Somatostatin receptor agonists and antagonists

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 9, 2003, Pages 1427-1441

  Crider, A Michael ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Somatostatin; Somatostatin receptors (sst); Somatotropin release inhibiting factor (SRIF); SRIF agonists; SRIF antagonists

Indexed keywords

CH 275; CYCLOPEPTIDE; CYN 154806; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GROWTH HORMONE; INSULIN; JF 0559; L 054522; L 779976; L 796778; L 803087; L 817818; NEUROTRANSMITTER; NNC 269100; OCTREOTIDE; PEPTIDE DERIVATIVE; PEPTIDE HORMONE; PTR 3173; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SEGLITIDE; SMS 201955; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR AGONIST; SOMATOSTATIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; GLUCAGON RELEASE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; INHIBITION KINETICS; INSULIN RELEASE; MOUSE; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN STRUCTURE; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR CELL;

EID: 0141517184     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.9.1427     Document Type: Review

References (83)

1. BRAZEAU P, VALE W, BURGUS R et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 179:77-79.
2. DE LECEA L, CRIADO JR, PROSPERO-GARCIA O et al.: A cortical neuropeptide with neuropeptide with neuronal depressant and sleep-modulating properties. Nature (1996) 381:242-245.
3. SPIER AD, DE LECEA L: A member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Rev. (2000) 33(2,3):228-241.
4. FUKUSUMI S, KITADA C, TAKEKA S et al.: Identification and characterization of a novel human cortistatin-like peptide. Biochem. Biophys. Res. Commun. (1997) 232:157-163.
5. 125I]-Tyr10-cortistatin labels all five somatostatin receptors. Naunyn Shmiedebergs Arch. Pharmacol. (1998) 375(5):483-489.
6. PUEBLA L, MOUCHANTAF R, SASI R et al.: Processing of rat preprocortistatin in mouse AtT-20 cells. J. Neurochem. (1999) 73:1273-1277.
7. DEGHENGHI R, PAPOTTI M, GHIGO E, MUCCIOLI G: Cortistatin, but not somatostatin, binds to growth hormone secretagoue (GSH) receptors of human pituitary. J. Endocrinol. Invest. (2001) 24:RC1-RC3.
8. DALM VA, VAN HAGEN MP, VAN KOETSVELD PM et al.: Cortistatin rather than somatostatin as a potential ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol. Metabol. (2003) 88:270-276.
9. HOYER D, BELL GI, BERELOWITZ M et al.: Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. (1995) 16:86-88.
10. BELL GI, REISINE T. Molecular biology of somatostatin receptors. Trends Neurosci. (1993) 16:34-38.
11. HANNON JP, NUNN C, STOTZ B et al.: Drug design at peptide, receptors. J. Mol. Neurosci. (2002) 18:15-27.
12. PIWKO C, THOSS VS, PROBST A, HOYER D: Localization and pharmacological characterization of somatostatin recognition sites in the human cerebellum. Neuropharmacology (1996) 35:713-723.
13. 2B receptor splice variant. Br. J. Pharmacol. (1998) 125:209-217.
14. 2B somatostatin receptor splice variant in rat brain and pituitary. Neuroendecrinology (1998) 68:37-43.
15. PATEL YC: Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. (1997) 20:348-367.
16. PATEL YC, GREENWOOD MT, PANETTA R, DEMCHYSHYN L, NIZNIK H, SRIKANT CB: The somatostatin receptor family: a mini review. Life Sci. (1995) 57:1249-1265.
17. PATEL YC: Somatostatin and its receptor family. Frontiers Neuroendocrinol. (1999) 20:157-158.
18. MURTHY KS, COY DH, MAKHOULF G: Somatostatin receptor mediated signaling in smooth muscle. J. Biol. Chem. (1996) 271:23458-23463.
19. SCHWEITZER R, MADAMBE S, SIGGINS GR: Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal m-current. Nature (1990) 346:464-467.
20. 2A. J. Biol. Chem. (2001) 276:14027-14036.
21. PFEIFFER M, KOCH T, SCHRODER H, LAUGSCH M, HOLLT V, SCHULZ S: Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. (2002) 277:19762-19772.
22. BREDER CD, YAMADA YY, YASUDA K et al.: Differential expression of somatostatin receptor subtypes in brain. J. Neurosci. (1992) 12:3920-3924.
23. KONG H, DE PAOLI AM, BREDER CD, YASUDA K, BELL GI, REISINE T. Differential expression of messenger RNA's for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brains: analysis by RNA blotting and in situ hybridization histochemistry. Neuroscience (1994) 59:175-184.
24. THOSS VS, PEREZ J, DUC D, HOYER D: Embryonic and postnatal mRNA distribution of five receptor subtypes in rat brain. Neuropharmacology (1995) 34:1673-1688.
25. DAY R, DONG W, PANETTA R, KRAICER J, GREENWOOD MT, PATEL YC: Expression of mRNA fbr somatostatin receptor (sstr) Types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology (1995) 136:5232-5235.
26. HOYER D, LUBBERT H, BRUNS C: Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1994) 350:441-453.
27. LE ROMANCER M, CHERIFI Y, LAVASSEUR S et al.: Messenger RNA expression of somatostatin receptor subtypes in human and gastric mucosae. Life Sci. (1996) 58:1091-1098.
28. BRUNO JF, XU Y, SONG J, BERELOWITZ M: Tissue distribution of somatostatin receptor subtype messenger ribonudeic acid in rat. Endocrinology (1993) 133:2561-2567.
29. CURTIS SB, HEWITT J, YAKUBOVITZ S, ANZARUT A, HSIANG YN, BUCHAN AM: Somatostatin receptor subtype expression and function in human vascular tissue. Am. J. Physiol. (2000) 278:1815-1822.
30. BATES CM, KEGG H, PETREVSKI C, GRADY S: Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. Kidney Int. (2003) 63:53-63.
31. 4 selectivity. Curr. Med. Chem. (1999) 6:401-410.
32. CULLER MD, TAYLOR JE, MOREAU JP: Somatostatin receptor subtypes: targeting functional and therapeutic specifity. Ann. Endocrinol. (2002) 63(2Part3):2S5-2S12.
33. STROWSKI MZ, PARMAR RM, BLAKE AD, SCHAEFFER JM: Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology (2000) 141:111-117.
34. STROWSKI MZ, KOHLER M, CHEN HY et al: Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. (2003) 17:93-106.
35. STROWSKI MZ, DASHKEVICZ MP, PARMAR RM et al.: Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology (2002) 75:339-346.
36. DRUCKER DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology (2002) 122:531-544.
37. STARK A, ROLF M: Somatostatin inhibits glucagon-like peptide-1 induced insulin secretion and proliferation of R1Nm5F insulinoma cells. Regul. Pept. (2002) 108:97-102.
38. CHISHOLM C, GREENBERG GR: Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am. J. Physiol. (2002) 283:(2Part1):E311-E317.
39. DI VITO L, BROGLIO F, BENSO A et al.: The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin. Endocrinol. (2002) 56:643-648.
40. BROGLIO F, VAN KOELSVELD P, BENSON A et al.: Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J. Clin. Endocrinol. Metabol. (2002) 87:4829-4832.
41. 0 and modulate GTPase activity in rabbit retina. J. Neurochem. (2003) 84:625-632.
42. 2 somatostatin receptor in mouse retina. Naunyn Schmiebergs Arch. Pharmacol. (2003) 367:186-192.
43. 2 receptors in rat retina. Neuropharmacology (2002) 43:899-909.
44. 5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. (2001) 28:836-846.
45. TEIJEIRO R, RIOS R, COSTOYA J et al.: Activation of human somatostatin receptor 2 promotes apotosis through a mechanism that is independent from induction of p53. Cell Physiol. Biochem. (2002) 12:31-38.
46. HALL GH, TURNBULL LW, RICHMOND I, HELBOE L, ATKIN SL: Localization of somatostatin and somatostatin receptors in benign and malignant ovarian tumors. Br. J. Cancer (2002) 87:86-90.
47. HANSSON J, BJARTELL A, GADALEANU V, DIZEYI N, ABRAHAMSSON PA: Expression of somatostatin receptor subtype 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 53:50-59.
48. LUTHERMAN K, HACKSELL U: Chapter 14. Peptides and peptidomimetics. In: A Textbook of Drug Design and Development. Krogsgaard-Larsen P, Lilejefors T, Madsen U (Eds), Harwood Academic Publishers, Amsterdam (1996):386-406.
49. VALE W, RIVIER J, LING N, BROWN M: Biologic and immunologic activities and applications of somatostatin analogues. Metabolism (1978) 27:1392-1401.
50. VEBER DF, SAPERSTEIN R, NUTT RF et al.: Super active hexapeptide analogues of somatostatin. Life Sci. (1984) 34:1371-1378.
51. BAUER W. BRINER U, DOEPFNER W et al.: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. (1982) 31:1133-1140.
52. LIAPAKIS G, HOEGER C, RIVIER J, REISINE T. Development of a selective agonist at the somatostatin receptor subtype ssr1. J. Pharmacol. Exp. Ther. (1996) 276:1089-1094.
53. 1). J. Med. Chem. (2001) 44:2238-2246.
54. RAJESWARAN WG, HOCART SJ, MURPHY WA, TAYLOR JE, COY DH: N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity. J. Med. Chem. (2001) 44:1416-1421.
55. AFARGAN M, JANSON ET, GELERMAN G et al: Novel long-acting somatostatin analogues with endocrine selectivity: potent suppression of growth hormone but not insulin. Endocrinology (2001) 142(1):477-486.
56. GAZAL S, GELERMAN G, ZIV O et al.: Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J. Med. Chem. (2002) 45:1665-1671.
57. GADEMANN K, KIMMERLIN T, HOYER D, SEEBACH D: Peptide folding induces high and selective affinity of a linear and small β-peptide to the human somatostatin receptor 4. J. Med. Chem. (2001) 44:2460-2468.
58. REUBI JC, EISENWIENER KP, RINK H, WASER B, MACKE HR: A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. (2002) 456:45-49.
59. SEEBACH D, SCHAEFFER L, BRENNER M, HOYER D: Design and synthesis of γ-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. Angew. Chem. Int. Ed. (2003) 42:776-778.
60. BASS RT, BUCKWALTER BL, PATEL BP et al.: Indentification and characterization of novel somatostatin antagonists. Mol. Pharmacol. (1996) 50:709-715.
61. HOCART SJ, JAIN R, MURPHY WA, TAYLOR JE, MORGAN B, COY DH: Potent antagonists of somatostatin: synthesis and biology. J. Med. Chem. (1998) 41:1146-1154.
62. HOCART SJ, JAIN R, MURPHY WA, TAYLOR JE, COY DH: Highly potent cyclic disulfide antagonists of somatostatin. J. Med. Chem. (1999) 42:1863-1871.
63. RAJESWAN WG, HOCART SJ, MURPHY WA, TAYLOR JE, COY DH: Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J. Med. Chem. (2001) 44:1305-1311.
64. RAJESWAN WG, MURPHY WA, TAYLOR JE, COY DH: Exploration of the D-Trp-N-MeLys motif in the search for potent somatostatin antagonists. Bioorg. Med. Chem. (2002) 10:2023-2030.
65. 3-Selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. USA (2000) 97:13973-13978.
66. 2 receptor antagonist CYN-154806. Naunyn Schmiedeberg's Arch. Pharmarol. (2003) 367:1-9.
67. CRIDER AM: Recent advances in the development of non-peptide somatostatin receptor ligands. Mini Rev. Med. Chem. (2002) 2:507-517.
68. HIRSCHMANN R, NICOLAOU K, PIETRANICO S et al.: Non-peptidal peptidomimetics with β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J. Am. Chem. Soc. (1992) 114:9217-9218.
69. HIRSCHMANN R, HYNES J Jr, CICHYKNIGHT MA et al.: Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis. J. Med. Chem. (1998) 41:1382-1391.
70. PRASAD V, BIRZIN ET, MC VAUGH CT et al.: Effects of heterocyclic aromatic substituents on binding affinities at two sites ofsomatostatin (SRIF) receptors. Correlation with electrostatic potential of the substituents. J. Med. Chem. (2003) 46:1858-1869.
71. 4 selectivity. J. Am. Chem. Soc. (1998) 120:1368-1373.
72. 4 selectivity: synthesis and structure-activity relationships of thioureas. J. Med. Chem. (1998) 41:4693-4705.
73. 2) agonists. J. Med. Chem. (1998) 41:2175-2179.
74. ROHRER SP, BIRZIN ET, MOSLEY RT et al.: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282:737-740.
75. BERK SC, ROHRER SP, DEGRADO SJ et al.: A combinatorial approach toward the discovery of non-peptide subtype-selective somatostatin receptor ligands. J. Comb. Chem. (1999) 1:388-396.
76. YANG L, BERK SC, ROHRER SP et al.: Synthesis and biological evaluation of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. USA (1998) 95:10836-10841.
77. PASTERNAK A, PAN Y, MARINO D et al.: Potent, orally-bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg. Med. Chem. Lett. (1999) 9:491-496.
78. SOUERS AJ, VIRGILLO AA, ROSENQUIST A et al.: Identification ofa potent heterocyclic ligand to somatostatin receptor subtype 5 by synthesis and screening of β-turn mimetic libraries. J. Am. Chem. Soc. (1999) 121:1817-1825.
79. GALCERA-CONTOUR MO, POITOUT L, MOINET C et al.: Synthesis of imidazopyrazines as ligands for the human somatostatin receptor subtype 5. Bioorg. Med. Chem. Lett. (2001) 11:741-745.
80. 3 receptor. Bioorg. Med. Chem. Lett. (2001) 11:991-996.
81. LIU J, UNDERWOOD DJ, CASCIERI MA et al.: Synthesis of a substance P antagonist with a somatostatin scaffold: factors affecting agonism/antagonism at GPCRs and the role pseudosymmetry. J. Med. Chem. (2000) 43:3827-3831.
82. HAY BA, COLE BM, DICAPUA F et al.: Small molecule somatostatin receptor subtype 2 antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2731-2734.
83. 2 receptor-selective antagonists. Eur. J. Pharmacol. (2003